LL schreef op 9 januari 2025 11:29:
BRIEF-Bayer Elinzanetant Meets All Primary And Secondary Endpoints In Phase III Study Oasis 4ELINZANETANT MEETS ALL PRIMARY AND SECONDARY ENDPOINTS IN PHASE III STUDY OASIS 4 FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS CAUSED BY BREAST CANCER TREATMENTS
Further company coverage: [BAYGn.DE]